BRPI0719995A2 - Composições e métodos para tratar distúrbios musculares & cardiovasculares - Google Patents

Composições e métodos para tratar distúrbios musculares & cardiovasculares

Info

Publication number
BRPI0719995A2
BRPI0719995A2 BRPI0719995-3A2A BRPI0719995A BRPI0719995A2 BR PI0719995 A2 BRPI0719995 A2 BR PI0719995A2 BR PI0719995 A BRPI0719995 A BR PI0719995A BR PI0719995 A2 BRPI0719995 A2 BR PI0719995A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
cardiovascular disorders
treat muscular
muscular
Prior art date
Application number
BRPI0719995-3A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Iwan Beuvink
Jonathan Hall
Jan Weiler
Christian Schnell
Matthias Mueller
Martina Schinke-Braun
Fabrizio Serluca
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0719995A2 publication Critical patent/BRPI0719995A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0719995-3A2A 2006-12-14 2007-12-13 Composições e métodos para tratar distúrbios musculares & cardiovasculares BRPI0719995A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86993706P 2006-12-14 2006-12-14
PCT/US2007/025535 WO2008076324A2 (en) 2006-12-14 2007-12-13 Compositions and methods to treat muscular & cardiovascular disorders

Publications (1)

Publication Number Publication Date
BRPI0719995A2 true BRPI0719995A2 (pt) 2014-03-18

Family

ID=39536897

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719995-3A2A BRPI0719995A2 (pt) 2006-12-14 2007-12-13 Composições e métodos para tratar distúrbios musculares & cardiovasculares

Country Status (11)

Country Link
US (3) US20100280094A1 (enExample)
EP (1) EP2104733A2 (enExample)
JP (3) JP2010512747A (enExample)
KR (1) KR20090098818A (enExample)
CN (2) CN101563458A (enExample)
AU (1) AU2007334502B2 (enExample)
BR (1) BRPI0719995A2 (enExample)
CA (1) CA2672606A1 (enExample)
EA (2) EA200900782A1 (enExample)
MX (1) MX2009006310A (enExample)
WO (1) WO2008076324A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659364C (en) 2006-08-01 2017-08-22 Board Of Regents Of The University Of Texas System Identification of a micro-rna that activates expression of .beta.-myosin heavy chain
EP2187896B1 (en) 2007-07-31 2016-01-13 The Board of Regents of The University of Texas System Inhibitors of mir-499 and mir-208b for use in the treatment of pathologic cardiac hypertrophy, heart failure or myocardial infarction
KR20110128838A (ko) 2009-02-04 2011-11-30 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심장 질환 치료에서 ｍｉｒ－208 및 ｍｉｒ－499의 이중 표적화
IE20090047A1 (en) * 2009-02-26 2010-09-29 Nat Univ Ireland Protein targets in disease
US9034605B2 (en) 2009-03-12 2015-05-19 Brandeis University Reagents and methods for PCR
WO2012083005A2 (en) 2010-12-15 2012-06-21 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
EP2763703B1 (en) 2011-10-06 2018-02-14 Miragen Therapeutics, Inc. Control of whole body energy homeostasis by microrna regulation
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
AU2013331434B2 (en) * 2012-10-15 2019-08-08 Ionis Pharmaceuticals, Inc. Compositions for modulating C90RF72 expression
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHOD FOR MONITORING THE C9ORF72 EXPRESSION
WO2014169126A1 (en) * 2013-04-10 2014-10-16 Reveragen Biopharma, Inc. Methods and agents to increase therapeutic dystrophin expression in muscle
CN112080502A (zh) 2013-10-11 2020-12-15 Ionis制药公司 用于调节c9orf72表达的组合物
CN108064175A (zh) * 2014-08-04 2018-05-22 米拉根医疗股份有限公司 Myh7b的抑制剂及其用途
AU2016209386A1 (en) 2015-01-20 2017-08-03 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
US9605263B2 (en) 2015-04-16 2017-03-28 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
CN106148519A (zh) * 2016-07-05 2016-11-23 无锡市第二人民医院 一种microRNA‑499的快速检测方法
WO2019014656A1 (en) 2017-07-14 2019-01-17 Han Si Ping METALLIC OLIGONUCLEOTIDE JONCTIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
WO2019033079A1 (en) * 2017-08-10 2019-02-14 City Of Hope CONDITIONAL RNAIDS AND THEIR USES IN THE TREATMENT OF CARDIAC HYPERTROPHY
KR102281710B1 (ko) 2021-02-19 2021-07-28 조기정 에어튜브를 이용한 선박 안전장치
CN119246849B (zh) * 2024-12-09 2025-03-14 上海基灵生物科技有限公司 一种检测犬心脏损伤的试剂盒及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
NZ239247A (en) * 1990-08-03 1993-11-25 Sterling Drug Inc Oligonucleosides containing a non-phosphate inter nucleoside linkage
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
JP3516167B2 (ja) * 1992-12-08 2004-04-05 ローム株式会社 タンタルコンデンサチップの製造方法
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DK1407044T4 (en) * 2000-12-01 2017-12-04 Max-Planck-Gesellschaft Zur Förderung Der Wss E V RNA interference mediating small RNA molecules
SG190613A1 (en) * 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
WO2005021800A2 (en) * 2003-08-22 2005-03-10 Sirna Therapeutics, Inc. Detection and quantitation of nucleic acid molecules in biological samples
EP1784501B1 (en) * 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
US8592384B2 (en) * 2005-04-04 2013-11-26 The Board Of Regents Of The University Of Texas System Micro-RNA's that regulate muscle cells
US20070092882A1 (en) * 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
ES2612903T3 (es) * 2006-01-10 2017-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Moléculas de ácido nucleico y colecciones de las mismas, su aplicación e identificación
CA2659364C (en) * 2006-08-01 2017-08-22 Board Of Regents Of The University Of Texas System Identification of a micro-rna that activates expression of .beta.-myosin heavy chain
EP2187896B1 (en) * 2007-07-31 2016-01-13 The Board of Regents of The University of Texas System Inhibitors of mir-499 and mir-208b for use in the treatment of pathologic cardiac hypertrophy, heart failure or myocardial infarction

Also Published As

Publication number Publication date
KR20090098818A (ko) 2009-09-17
AU2007334502A1 (en) 2008-06-26
US20100280094A1 (en) 2010-11-04
JP2010512747A (ja) 2010-04-30
WO2008076324A3 (en) 2009-04-09
EA201101361A1 (ru) 2012-11-30
JP2012019789A (ja) 2012-02-02
US20120041052A1 (en) 2012-02-16
MX2009006310A (es) 2009-07-22
WO2008076324A2 (en) 2008-06-26
EP2104733A2 (en) 2009-09-30
US20120114744A1 (en) 2012-05-10
CN102604951A (zh) 2012-07-25
EA200900782A1 (ru) 2009-12-30
CN101563458A (zh) 2009-10-21
AU2007334502B2 (en) 2011-12-15
JP2012131812A (ja) 2012-07-12
CA2672606A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
BRPI0719995A2 (pt) Composições e métodos para tratar distúrbios musculares & cardiovasculares
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
BRPI1014522A2 (pt) composicoes e metodos para aumentar o crescimento muscular
BRPI0815407A2 (pt) Composições e métodos para controlar nematódeos
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
SMT201500176B (it) Composizioni e metodi per inibire l'espressione ditranstiretina
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
EP2068927A4 (en) PROCESS FOR REDUCING EOSINOPHILLE MIRROR
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
ZA201001107B (en) Citrus oil compositions and methods of use
SG2014014153A (en) Preventing and/or treatingmetabolic disorders by modulatingthe amount of enterobacteria
IL204776A0 (en) Parp inhibitor compounds, compositions and methods of use
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
EP2405755A4 (en) METHOD AND COMPOSITIONS FOR TREATING METABOLISM AND CARDIOVASCULAR DISEASES
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
HUE050319T2 (hu) Kompozíciók és eljárások alkoholfogyasztással kapcsolatos rendellenességek, fájdalom és más betegségek kezelésére
EP2309858A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
SI2300614T1 (sl) Metode in sestavki za zdravljenje mitohondrijskih motenj
IL194189A0 (en) Combination treatment of metabolic disorders
PL2307000T3 (pl) Połączenie pilokarpiny i metimazolu do leczenia choroby Charcota-Mariegotootha i pokrewnych zaburzeń

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.